Press Releases

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
Featured News

Published 25 Feb, 2026

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Media Coverage

Novo Nordisk Inks A $2.1 Billion Deal To Develop Next Generation Obesity Pills

Published 25 Feb, 2026

Novo Nordisk Inks A $2.1 Billion Deal To Develop Next Generation Obesity Pills

Reuters

Novo Nordisk, Vivtex announce deal for weight-loss pill

Published 25 Feb, 2026

Novo Nordisk, Vivtex announce deal for weight-loss pill

The Boston Globe

Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess

Published 25 Feb, 2026

Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess

Fierce

Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs

Published 24 Nov, 2020

Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs

Reuters

Further Media Coverage

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

Endpoints

Published 25, Feb 2026

Novo Nordisk Licenses Vivtex Tech for Up to $2.1 Billion to Deepen Obesity Push

The Wall Street Journal

Published 25, Feb 2026

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Bloomberg

Published 25, Feb 2026

With Vivtex deal, Novo gains a chance at better oral obesity drugs

Biopharma Dive

Published 25 Feb, 2026

Novo turns to Vivtex for oral obesity biologics in $2.1B deal

Firstword Pharma

Published 25 Feb, 2026

Novo Nordisk forms $2.1B partnership to develop oral obesity drugs

Axios

Published 25 Feb, 2026

Langer-founded biotech lands massive Novo Nordisk deal as obesity drug race heats up

Boston Business Journal

Published 25 Feb, 2026

Novo Enlists Vivtex For Next-Gen Oral Obesity And Diabetes Biologics

Citeline

Published 25 Feb, 2026